重症监护病房中严格与宽松血糖控制:糖尿病患者的特殊考量
应激性高血糖、低血糖和糖尿病在重症患者中常见并与临床终点相关。目前推荐对多数持续血糖>10·0 mmol/L(>180 mg/dL)的重症患者启动胰岛素治疗,目标7·8-10·0 mmol/L(140-180 mg/dL)。本文评述近期随机对照试验对现行推荐的挑战,并讨论合并与未合并糖尿病的重症患者间的差异及该人群的显著异质性。
要点
- 推荐对多数持续血糖>10·0 mmol/L(>180 mg/dL)的重症患者启动胰岛素治疗,目标7·8-10·0 mmol/L(140-180 mg/dL)。
- 近期随机对照临床试验对现行血糖控制推荐提出挑战。
- 合并与未合并糖尿病的重症患者存在重要差异,且该人群异质性显著。
核心结论
- 近期随机对照临床试验对现行血糖控制推荐提出挑战,合并与未合并糖尿病的重症患者间存在重要差异。
研究设计与样本
- 个人观点(Personal View)文章,评述前瞻性随机对照试验与观察性研究中血糖控制安全性及有效性的证据,聚焦重症监护病房中的糖尿病患者。
主要发现
- 应激性高血糖、低血糖和糖尿病在重症患者中常见并与临床终点相关。
- 为避���低血糖和高血糖相关并发症,推荐对多数持续血糖>10·0 mmol/L(>180 mg/dL)的重症患者启动胰岛素治疗,目标7·8-10·0 mmol/L(140-180 mg/dL)。
- 血糖管理的循证目标尤其对糖尿病患者仍在争论中。
关键数值与推荐
- 持续血糖>10·0 mmol/L(>180 mg/dL)的多数重症患者启动胰岛素治疗,目标范围7·8-10·0 mmol/L(140-180 mg/dL)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stress hyperglycaemia, hypoglycaemia, and diabetes are common in critically ill patients and related to clinical endpoints. To avoid complications related to hypoglycaemia and hyperglycaemia, it is recommended to start insulin therapy for the majority of critically ill patients with persistent blood glucose concentrations higher than 10·0 mmol/L (>180 mg/dL), targeting a range of 7·8-10·0 mmol/L (140-180 mg/dL). However, management and evidence-based targets for blood glucose control are under debate, particularly for patients with diabetes. Recent randomised controlled clinical trials now challenge current recommendations. In this Personal View, we aim to highlight these developments and the important differences between critically ill patients with and without diabetes, taking into account the considerable heterogeneity in this patient group. We critically discuss evidence from prospective randomised controlled trials and observational studies on the safety and efficacy of glycaemic control, specifically in the context of patients with diabetes in intensive care units.
引用
- von Loeffelholz C, Birkenfeld AL. Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes. Lancet Diabetes Endocrinol. 2024. PMID: 38514241. doi:10.1016/S2213-8587(24)00058-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。